Case Report: Nintedanib for Pembrolizumab-Related Pneumonitis in a Patient With Non-Small Cell Lung Cancer

被引：10

作者：

Xie, Xiao-Hong ^{[1
]}

Deng, Hai-Yi ^{[1
]}

Lin, Xin-Qing ^{[1
]}

Wu, Jian-Hui ^{[1
]}

Liu, Ming ^{[1
]}

Xie, Zhan-Hong ^{[1
]}

Qin, Yin-Yin ^{[1
]}

Zhou, Cheng-Zhi ^{[1
]}

机构：

[1] Guangzhou Med Univ, Affiliated Hosp 1, Natl Clin Res Ctr Resp Dis, Stale Key Lab Resp Dis,Guangzhou Inst Resp Hlth, Guangzhou, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2021年 / 11卷

关键词：

checkpoint inhibitor-related pneumonitis; nintedanib; steroid therapy; non-small cell lung cancer; pembrolizumab; IMMUNOTHERAPY;

D O I：

10.3389/fonc.2021.673877

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pembrolizumab, an immune checkpoint inhibitor (ICI) approved for advanced non-small cell lung cancer (NSCLC) treatment, has shown superior survival benefits. However, pembrolizumab may lead to severe immune-related adverse events (irAEs), such as checkpoint inhibitor-related pneumonitis (CIP). The routine treatment of CIP was based on systemic corticosteroids, but the therapies are limited for patients who are unsuitable for steroid therapy. Here, we present the first successful treatment of nintedanib for pembrolizumab-related pneumonitis in a patient with advanced NSCLC.

引用

页数：4

共 50 条

[41] Pembrolizumab in non-small cell lung cancer: our experience
Rizvi, S. A.
Reza, S.
Kabba, T.
Ajzensztejn, D.
Dwyer, M.
Randhawa, R.
Karina, M.
LUNG CANCER, 2019, 127 : S83 - S83
[42] Advanced non-small cell lung cancer - Treatment with Pembrolizumab
Silvinato, Antonio
Floriono, Idevaldo
Bernardo, Wanderley Marques
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2019, 65 (12): : 1423 - 1432
[43] Case report: Pharmacokinetics of pembrolizumab in a patient with stage IV non-small cell lung cancer after a single 200 mg administration
de Vries, Fenna
Smit, Adrianus A. J.
Wolbink, Gertjan
de Vries, Annick
Loeff, Floris C. C.
Franssen, Eric J. F.
FRONTIERS IN ONCOLOGY, 2023, 12
[44] Pembrolizumab combined with stereotactic body radiotherapy in a patient with human immunodeficiency virus and advanced non-small cell lung cancer: A case report
Li D.
He C.
Xia Y.
Du Y.
Zhang J.
Journal of Medical Case Reports, 12 (1)
[45] Nintedanib in non-small cell lung cancer: from preclinical to approval
Caglevic, Christian
Grassi, Massimiliano
Raez, Luis
Listi, Angela
Giallombardo, Marco
Bustamante, Eva
Gil-Bazo, Ignacio
Rolfo, Christian
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2015, 9 (04) : 164 - 172
[46] Response of Pembrolizumab Alone for Non-small Cell Lung Cancer With Brain Metastasis: A Case Report and Literature Review
Marvin, Eric A.
Furrow, Kimberley L.
Kar, Ayesha
Cuoco, Joshua A.
FRONTIERS IN ONCOLOGY, 2020, 10
[47] Psoriasis induced by first-line pembrolizumab in metastatic non-small cell lung cancer: A case report
Gatti, Federica
Caruso, Gianluca
Potenza, Concetta
Santini, Daniele
Petrozza, Vincenzo
Annetta, Alessandro
Ceddia, Serena
Cosimati, Antonella
Brandi, Martina
Sorrentino, Veronica
Proietti, Ilaria
Rossi, Luigi
ONCOLOGY LETTERS, 2023, 26 (01)
[48] Pembrolizumab for non-small cell lung cancer with central nervous system metastases: A two-case report
Di, Mingyi
Zhang, Li
THORACIC CANCER, 2019, 10 (02) : 381 - 385
[49] Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patient
Ito, Munehiro
Kanda, Shintaro
Yoshida, Tatsuya
Okuma, Yusuke
Jo, Hitomi
Fukuhara, Suguru
Maeshima, Akiko Miyagi
Ohe, Yuichiro
LUNG CANCER, 2020, 146 : 362 - 365
[50] Atezolizumab and nintedanib in patients with non-small cell lung cancer and interstitial lung disease
Yamaguchi, Teppei
Shimizu, Junichi
Shigematsu, Fumie
Watanabe, Naohiro
Hasegawa, Takaaki
Horio, Yoshitsugu
Inaba, Yoshitaka
Fujiwara, Yutaka
JOURNAL OF THORACIC DISEASE, 2024, 16 (05) : 3371 - 3380

← 1 2 3 4 5 →